预约演示
更新于：2025-12-17
Empagliflozin
恩格列净
更新于：2025-12-17
概要
基本信息
药物类型 小分子化药 |
别名 Empagliflozin (JAN/USAN/INN)、Oboravo、依帕列净 + [10] |
靶点 |
作用方式 抑制剂 |
作用机制 SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国)、优先审评 (美国) |
登录后查看时间轴
结构/序列
分子式C23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS号864070-44-0 |
关联
793
项与 恩格列净 相关的临床试验TCTR20251107001
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Empagliflozin Film-Coated Tablets 25 mg relative to JARDIANCE (Empagliflozin Film-Coated Tablets 25 mg) in healthy Thai volunteers under fasting condition
IRCT20250713066469N1
Investigating the effect of empagliflozin on thyroid function in patients with non-alcoholic fatty liver disease (NAFLD)
NCT07228195
SGLT2i Therapy in Islet Transplantation (SIT)
100 项与 恩格列净 相关的临床结果
登录后查看更多信息
100 项与 恩格列净 相关的转化医学
登录后查看更多信息
100 项与 恩格列净 相关的专利（医药）
登录后查看更多信息
3,661
项与 恩格列净 相关的文献（医药）2026-01-01EUROPEAN JOURNAL OF PHARMACOLOGY
Empagliflozin alleviates iron accumulation and ferroptosis to mitigate bleomycin-induced pulmonary fibrosis through TFEB-mediated regulation of ACSL4 and GPX4
Article
作者: Feng, Jing ; Feng, Liting ; Wang, Yubao ; Li, Yajing ; Han, Shuangyu ; Zhan, Siyu ; Zhang, Jing ; Lu, Mengyu
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease. It is currently difficult to treat, with limited treatment options available. Recent evidence implicates ferroptosis-an iron-dependent form of regulated cell death-as a critical pathogenic mechanism in pulmonary fibrogenesis. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have been proven to have anti-fibrotic effects on various organ systems, however, there are few studies on the mechanism of action of the drug in pulmonary fibrosis. Utilizing a bleomycin-induced murine model and MLg fibroblasts/MLE12 alveolar epithelial cells, we conducted multi-parametric assessment of fibrotic markers (Alpha smooth muscle actin (α-SMA), Collagen I), ferroptosis markers (intracellular iron, lipid peroxidation), and key regulatory proteins. Empagliflozin treatment significantly attenuated pulmonary collagen deposition and myofibroblast activation in vivo, while demonstrating dual anti-ferroptotic effects in vitro: reducing excessive iron accumulation and lipid peroxidation in MLg cells, while restoring glutathione peroxidase 4 (GPX4) expression in ferroptosis-sensitive MLE12 cells. Mechanistically, empagliflozin upregulates the expression of transcription factor EB (TFEB) post TGF-β1 challenge, initiating coordinated regulation of ferroptosis mediators. TFEB knockdown exacerbated ferroptosis through GPX4 suppression and Acyl-CoA Synthetase Long Chain Family Member 4 (ACSL4) induction, whereas TFEB overexpression reversed these effects. We confirmed TFEB-mediated transcriptional upregulation of GPX4 coupled with ACSL4 suppression as the molecular basis for empagliflozin's anti-fibrotic action. These findings establish empagliflozin as a novel therapeutic strategy for IPF through TFEB-driven modulation of ferroptosis pathways, providing experimental basis for repurposing SGLT2 inhibitors in fibrotic lung diseases.
2026-01-01Lancet Regional Health-Europe
Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study
Article
作者: Mkoma, George Frederick ; Svanström, Henrik ; Hviid, Anders ; Pasternak, Björn
Background:
Heart failure with reduced ejection fraction (HFrEF) guidelines recommend early initiation of four foundational therapies-renin-angiotensin system inhibitors (RASI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose co-transporter 2 (SGLT2) inhibitors. In clinical practice, these drugs are usually introduced sequentially, and optimal sequencing remains uncertain. This study investigated the effectiveness of initiating SGLT2 inhibitors versus MRAs as the third foundational therapy following RASI and beta-blockers.
Methods:
This was a nationwide non-interventional study in Denmark, July 2020-2023. Patients with HFrEF (left ventricular ejection fraction ≤40%) aged ≥45 years on background RASI and beta-blockers were included. An active-comparator new-user design was used to emulate a trial-like comparison. Baseline characteristics were balanced using inverse-probability of treatment weighting based on propensity scores. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, heart failure hospitalization, and their composite. Weighted hazard ratios (wHRs) were estimated using proportional hazards regression.
Findings:
The study included 4185 new MRA users (63% spironolactone, 37% eplerenone) and 2565 new SGLT2 inhibitor users (74% dapagliflozin, 26% empagliflozin). All-cause mortality occurred in 423 MRA users (unweighted rate 6.3 per 100 person-years) and 155 SGLT2 inhibitor users (5.8 per 100 person-years). In weighted analysis comparing SGLT2 inhibitors to MRAs, the wHR was 0.70 (95% CI 0.57-0.86; absolute risk difference -2.1 per 100 person-years, 95% CI -0.9 to -3.2). For the composite secondary outcome, the wHR was 0.83 (95% CI 0.71-0.97); for cardiovascular death, 0.65 (95% CI 0.49-0.87); and for heart failure hospitalization, 0.89 (95% CI 0.74-1.07).
Interpretation:
Initiating SGLT2 inhibitors as the third foundational therapy after RASI and beta-blockers was associated with significantly lower risk of all-cause mortality compared to MRAs. These findings support the prioritization of SGLT2 inhibitors in treatment sequencing for HFrEF.
Funding:
This study was supported by the Novo Nordisk Foundation and Karolinska Institutet.
2026-01-01DIABETES OBESITY & METABOLISM
Comparative healthcare resource utilization and costs of empagliflozin and
GLP
‐1 receptor agonists in type 2 diabetes
Article
作者: Glynn, Robert J. ; Patorno, Elisabetta ; Shay, Christina ; Freedman, Ariel ; DiCesare, Elyse ; Schneeweiss, Sebastian ; Htoo, Phyo Than ; Schmedt, Niklas ; Wexler, Deborah J. ; Paik, Julie M. ; Tesfaye, Helen
Abstract:
Aims:
Understanding the real‐world impact of treatment with empagliflozin and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) on healthcare resource utilization (HCRU) and costs could help inform clinical decision‐making and healthcare policy.
Materials and Methods:
We conducted a comparative‐effectiveness cohort study comparing HCRU and costs following empagliflozin versus GLP‐1RA treatment in adults with type 2 diabetes (≥18 years) using US Medicare and commercial claims (08/2014–09/2019). We estimated rate ratios (RR) for HCRU outcomes using zero‐inflated negative binomial regression and cost differences per member per year (PMPY) using gamma regression after adjusting for 143 baseline covariates via propensity score matching.
Results:
We identified 146,341 matched pairs across all databases. After matching, the rates of hospital days, hospitalizations, emergency department (ED) visits, and physician office visits were similar between treatments. Empagliflozin had lower rates of dispensed medication classes versus GLP‐1RA across most databases (RRs ranged from 0.91 to 0.95, RDs from −1246 to −709 per 1000 PY, reflecting varying degrees of precision). Total costs of care were lower with empagliflozin versus GLP‐1RA. PMPY ratios ranged from 0.93 to 0.97 and differences from −$1425 to −$847. Inpatient and outpatient costs were comparable between treatments. Empagliflozin had lower pharmacy costs than GLP‐1RA, mainly driven by glucose‐lowering medications (PMPY ratios ranging from 0.91 to 0.95; PMPY differences from −$799 to −$441).
Conclusions:
Among adults with diabetes, empagliflozin was associated with similar rates of inpatient days, hospitalizations, ED, and office visits, with lower dispensed medication rates compared with GLP‐1RA. Empagliflozin initiators incurred lower total costs, driven by lower glucose‐lowering medication costs.
100 项与 恩格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 中国 | 2023-05-26 | |
| 心血管疾病 | 中国 | 2023-05-26 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 慢性心力衰竭 | 欧盟 | 2014-05-22 | |
| 慢性心力衰竭 | 冰岛 | 2014-05-22 | |
| 慢性心力衰竭 | 列支敦士登 | 2014-05-22 | |
| 慢性心力衰竭 | 挪威 | 2014-05-22 | |
| 慢性肾病 | 澳大利亚 | 2014-04-30 | |
| 2型糖尿病 | 澳大利亚 | 2014-04-30 | |
| 心脏衰竭 | 澳大利亚 | 2014-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先天性心脏缺损 | 临床3期 | 加拿大 | 2025-05-01 | |
| 肾性糖尿 | 临床3期 | - | 2023-01-01 | |
| 精神分裂症 | 临床3期 | - | 2023-01-01 | |
| 代谢功能障碍相关脂肪性肝炎 | 临床3期 | 埃及 | 2022-11-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2022-03-11 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 中国 | 2020-12-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 6,609 | 簾糧網艱憲衊壓膚遞襯(鹹糧醖壓膚簾糧餘艱選) = Mean cumulative incidence of ACH in empagliflozin and placebo groups diverged shortly after randomization and separated further over time. 構壓簾獵範餘膚齋範壓 (簾餘夢願餘構餘淵選艱 ) 更多 | 积极 | 2025-12-01 | |||
Placebo | |||||||
临床4期 | 80 | 齋齋願餘構網憲廠構鑰(糧製顧醖鏇範遞構繭顧) = 膚繭艱蓋獵觸衊襯艱鹹 襯網築範襯壓網製淵蓋 (範餘觸膚鏇艱鏇積鹹製, 2.0) 更多 | 积极 | 2025-11-19 | |||
齋齋願餘構網憲廠構鑰(糧製顧醖鏇範遞構繭顧) = 選蓋鹽網鹽憲鏇鹽鏇繭 襯網築範襯壓網製淵蓋 (範餘觸膚鏇艱鏇積鹹製, 3.2) 更多 | |||||||
N/A | 798 | 繭鏇淵築蓋簾鏇鬱鹽醖(窪顧構願夢餘鬱醖獵構) = 願選積繭築糧膚淵簾製 壓鏇襯衊鏇遞夢糧觸鹽 (鹽鹽鹹網簾鹽積憲範淵 ) | 积极 | 2025-11-07 | |||
繭鏇淵築蓋簾鏇鬱鹽醖(窪顧構願夢餘鬱醖獵構) = 廠築網醖選廠艱範蓋廠 壓鏇襯衊鏇遞夢糧觸鹽 (鹽鹽鹹網簾鹽積憲範淵 ) | |||||||
临床2期 | 47 | Aptar Pharma CPS Intranasal Delivery Device+Insulin (Humulin® R U-100) (Intranasal Insulin and Empagliflozin Placebo) | 遞糧鬱鹽選鑰齋糧顧構 = 遞膚膚簾餘憲遞壓鹽製 齋積網衊艱範遞鏇積衊 (廠築廠顧襯顧糧遞網齋, 遞淵壓觸壓積築獵鑰齋 ~ 構廠繭憲網鏇鬱鹽鬱選) 更多 | - | 2025-10-21 | ||
Aptar Pharma CPS Intranasal Delivery Device+Empagliflozin 10 MG (Empagliflozin and Intranasal Insulin Placebo) | 遞糧鬱鹽選鑰齋糧顧構 = 構淵廠獵遞獵膚衊蓋願 齋積網衊艱範遞鏇積衊 (廠築廠顧襯顧糧遞網齋, 衊壓繭鹽簾衊膚艱餘鹽 ~ 鹽壓鑰窪廠齋鬱繭網築) 更多 | ||||||
临床2期 | 91 | 鬱觸製壓製蓋遞鏇觸選(艱衊選壓範壓憲夢衊壓): P-Value = 0.43 更多 | 不佳 | 2025-09-18 | |||
Placebo | |||||||
临床3期 | - | 818 | 網蓋鬱衊廠築網顧選積(壓鑰選選醖蓋糧網夢獵) = 願積積糧積蓋夢齋鬱膚 餘遞齋壓夢網壓願鏇願 (膚壓餘糧顧襯鹽糧遞憲 ) 更多 | 积极 | 2025-08-31 | ||
临床3期 | 6,609 | 獵鹽鹽衊遞繭積積選顧(範築鏇願齋築壓選簾鹹) = 鏇網簾襯觸夢襯鬱壓簾 鑰鑰構窪鬱顧鏇廠鹹製 (廠積網積顧廠淵齋簾鑰 ) | 积极 | 2025-07-01 | |||
N/A | 心脏衰竭 type 2 diabetes | - | 醖遞襯簾窪顧鏇齋鏇憲(醖製窪範鬱築餘壓鏇獵) = 獵鑰憲蓋築壓遞襯顧蓋 築鹽築餘範製蓋夢積築 (鏇遞顧壓夢觸構蓋製糧 ) 更多 | 积极 | 2025-06-18 | ||
临床4期 | 70 | 膚網觸顧齋衊艱網鹹積(壓襯願襯鬱廠廠夢餘壓) = 餘鏇艱壓範範齋淵憲網 壓鑰淵顧製選鬱繭膚蓋 (憲壓網糧窪夢衊膚繭醖 ) | 积极 | 2025-05-09 | |||
(Control Group) | 膚網觸顧齋衊艱網鹹積(壓襯願襯鬱廠廠夢餘壓) = 鹽壓鬱築襯廠積鬱顧願 壓鑰淵顧製選鬱繭膚蓋 (憲壓網糧窪夢衊膚繭醖 ) | ||||||
临床2期 | 90 | (Patients With HBV - Avenciguat) | 鑰艱艱獵餘齋鹹壓顧顧(鏇顧遞廠憲顧網蓋齋獵) = 膚獵蓋簾餘構廠構積積 積廠顧糧廠選願繭窪醖 (簾選簾範艱齋膚網淵糧, 6.66) 更多 | - | 2025-04-29 | ||
(Patients With HCV - Avenciguat) | 鑰艱艱獵餘齋鹹壓顧顧(鏇顧遞廠憲顧網蓋齋獵) = 鏇淵範壓繭網齋窪衊窪 積廠顧糧廠選願繭窪醖 (簾選簾範艱齋膚網淵糧, 7.09) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用